Cytalux
(CYTALUX™ (pafolacianine) injection preoperatively)Phase 2Small molecule
Cytalux is one of 20 small molecule programs targeting Intraoperative. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Intraoperative
#DrugCompanyPhaseTrials
1Zofran
NovartisApproved
IC-Green
PProvepharm SAS
Approved
Ketalar
AAultman Health Foundation
Approved
Anerem
AAcacia Pharma Ltd
Approved
Reglan
IIstituto Clinico Humanitas
Approved
Ciprofol
Haisco Pharmaceutical Group Co., Ltd.Phase 3
MS Contin
HHikma Pharmaceuticals LLC
Phase 2
Vancocin
HHikma Pharmaceuticals LLC
Phase 2
Marcaine
IInnocoll
Phase 2
Robinul
Jazz PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Nov 29, 2021
CYTALUX
NDA NDA214907
Sources
References
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- OOn Target Laboratories, LLC